It is increasingly recognized that the tumor microenvironment plays a critical role in the initiation and progression of lung cancer. In particular interaction of cancer cells, macrophages, and inflammatory response in the tumor microenvironment has been shown to facilitate cancer cell invasion and metastasis. The specific molecular pathways in macrophages that immunoedit tumor growth are not well defined. Triggering receptor expressed on myeloid cells 1 (TREM-1) is a member of the super immunoglobulin family expressed on a select group of myeloid cells mainly monocyte/macrophages. Recent studies suggest that expression of TREM-1 in tumors may predict cancer aggressiveness and disease outcomes in liver and lung cancer however the mechanism of TREM-1 expression in the setting of cancer is not defined. In this study we demonstrate that tumor tissue from patients with non-small cell lung cancer show an increased expression of TREM-1 and PGE2. Immunohistochemistry and immunofluorescence confirmed that the expression of TREM-1 was selectively seen in CD68 positive macrophages. By employing an in vitro model we confirmed that expression of TREM-1 is increased in macrophages that are co-cultured with human lung cancer cells. Studies with COX-2 inhibitors and siCOX-2 showed that expression of TREM-1 in macrophages in tumor microenvironment is dependent on COX-2 signaling. These studies for the first time define a link between tumor COX-2 induction, PGE2 production and expression of TREM-1 in macrophages in tumor microenvironment and suggest that TREM-1 might be a novel target for tumor immunomodulation.
References
[1]
Carbone DP, Felip E (2011) Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. Clin Lung Cancer 12: 261–271.
[2]
Detterbeck FC, Boffa DJ, Tanoue LT (2009) The new lung cancer staging system. Chest 136: 260–271.
[3]
Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different! J Exp Med. 193: F23–26.
[4]
Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78.
[5]
Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263–274.
[6]
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674.
[7]
Hallam S, Escorcio-Correia M, Soper R, Schultheiss A, Hagemann T (2009) Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol 219: 143–152.
[8]
Brower V (2012) Macrophages: cancer therapy’s double-edged sword. J Natl Cancer Inst 104: 649–652.
[9]
Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122: 787–795.
[10]
Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267: 204–215.
[11]
Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958–969.
[12]
Murray PJ, Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11: 723–737.
[13]
Allavena P, Mantovani A (2012) Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167: 195–205.
[14]
Lievense LA, Bezemer K, Aerts JG, Hegmans JP (2013) Tumor-associated macrophages in thoracic malignancies. Lung Cancer 80: 256–262.
[15]
Bouchon A, Facchetti F, Weigand MA, Colonna M (2001) TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410: 1103–1107.
[16]
Sharif O, Knapp S (2008) From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213: 701–713.
[17]
Tessarz AS, Cerwenka A (2008) The TREM-1/DAP12 pathway. Immunol Lett 116: 111–116.
[18]
Bouchon A, Dietrich J, Colonna M (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164: 4991–4995.
[19]
Yuan Z, Syed MA, Panchal D, Rogers D, Joo M, et al. (2012) Curcumin mediated epigenetic modulation inhibits TREM-1 expression in response to lipopolysaccharide. Int J Biochem Cell Biol 44: 2032–2043.
[20]
Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21: 38–46.
[21]
Zeng H, Ornatowska M, Joo MS, Sadikot RT (2007) TREM-1 expression in macrophages is regulated at transcriptional level by NF-kappaB and PU.1. Eur J Immunol 37: 2300–2308.
[22]
Ornatowska M, Azim AC, Wang X, Christman JW, Xiao L, et al. (2007) Functional genomics of silencing TREM-1 on TLR4 signaling in macrophages. Am J Physiol Lung Cell Mol Physiol 293: L1377–1384.
[23]
Murakami Y, Kohsaka H, Kitasato H, Akahoshi T (2007) Lipopolysaccharide-induced up-regulation of triggering receptor expressed on myeloid cells-1 expression on macrophages is regulated by endogenous prostaglandin E2. J Immunol 178: 1144–1150.
[24]
Syed MA, Joo M, Abbas Z, Rodger D, Christman JW, et al. (2010) Expression of TREM-1 is inhibited by PGD2 and PGJ2 in macrophages. Exp Cell Res 316: 3140–3149.
[25]
Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, et al. (2012) The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res 72: 3977–3986.
[26]
Liao R, Sun TW, Yi Y, Wu H, Li YW, et al. (2012) Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma. Cancer Sci 103: 984–992.
[27]
Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, et al. (2008) TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 177: 763–770.
[28]
Sadikot RT, Zeng H, Azim AC, Joo M, Dey SK, et al. (2007) Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2. Eur J Immunol 37: 1001–1009.
[29]
Lee JM, Mao JT, Krysan K, Dubinett SM (2007) Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol 3: 149–153.
[30]
Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188: 21–28.
[31]
Hata AN, Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147–166.
[32]
Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331: 1565–1570.
[33]
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539–545.
[34]
Ben-Neriah Y, Karin M (2011) Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12: 715–723.
[35]
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867.
[36]
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436–444.
[37]
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239–252.
[38]
Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, et al. (2001) Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 92: 2399–2405.
[39]
Takanami I, Takeuchi K, Kodaira S (1999) Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology (Williston Park) 57: 138–142.
[40]
Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, et al. (2011) Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol 28: 1447–1452.
[41]
Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, et al. (2010) Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol 5: 1507–1515.
[42]
Heusinkveld M, van der Burg SH (2011) Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 9: 216.
[43]
Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, et al. (2012) Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 4: 291–304.
[44]
Wang R, Zhang J, Chen S, Lu M, Luo X, et al. (2011) Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 74: 188–196.
[45]
Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, et al. (2008) Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res 6: 364–371.
[46]
Steidl C, Lee T, Shah SP, Farinha P, Han G, et al. (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362: 875–885.
[47]
Zhang B, Yao G, Zhang Y, Gao J, Yang B, et al. (2011) M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 66: 1879–1886.
[48]
Holgersson G, Sandelin M, Hoye E, Bergstrom S, Henriksson R, et al. (2012) Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol 29: 3176–3182.
[49]
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, et al. (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222–225.
[50]
Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, et al. (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19: 512–526.
[51]
Beane J, Sebastiani P, Whitfield TH, Steiling K, Dumas YM, et al. (2008) A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res (Phila) 1: 56–64.
[52]
Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL (2008) Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol 180: 3520–3534.
Teng MW, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, et al. (2010) IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A 107: 8328–8333.
[55]
Baird AM, Leonard J, Naicker KM, Kilmartin L, O’Byrne KJ, et al. (2013) IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer 79: 83–90.
[56]
Chen J, Liu RY, Yang L, Zhao J, Zhao X, et al. (2013) A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol 139: 231–242.
[57]
Lim BJ, Jung SS, Choi SY, Lee CS (2010) Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol Med Rep 3: 43–49.
[58]
Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, et al. (2002) Regular aspirin use and lung cancer risk. BMC Cancer 2: 31.
[59]
Wang X, Li G, Wang A, Zhang Z, Merchan JR, et al. (2013) Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog 52: 218–228.
[60]
Qiu R, Chen J, Sima J, Shen X, Liu D, et al. (2012) NS398 induces apoptosis in non-small cell lung cancer cells. J Cancer Res Clin Oncol 138: 119–124.
[61]
Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, et al. (2011) Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4: 984–993.
